



**Correction to
Lancet Microbe 2022;
3: e435–42**

Armstrong E, Hemmerling A, Miller S, et al. Sustained effect of LACTIN-V (*Lactobacillus crispatus* CTV-05) on genital immunology following standard bacterial vaginosis treatment: results from a randomised, placebo-controlled trial. *Lancet Microbe* 2022; 3: e435–42—In this Article, the number of participants in the larger LACTIN-V clinical trial from which the sub-analysis was performed should have been 228 throughout the Article. This correction has been made as of June 2, 2022.

Published Online
June 2, 2022
[https://doi.org/10.1016/S2666-5247\(22\)00156-2](https://doi.org/10.1016/S2666-5247(22)00156-2)